$39.6 M

OBLN Mkt cap, 14-Dec-2018

$3 M

Obalon Therapeutics Revenue Q3, 2018
Obalon Therapeutics Gross profit (Q3, 2018)1.6 M
Obalon Therapeutics Gross profit margin (Q3, 2018), %52.5%
Obalon Therapeutics Net income (Q3, 2018)-6.7 M
Obalon Therapeutics EBIT (Q3, 2018)-6.6 M
Obalon Therapeutics Cash, 30-Sep-201821.6 M

Obalon Therapeutics Income Statement

Annual

USDFY, 2016FY, 2017

Revenue

9.9m

Cost of goods sold

2.8m4.8m

Gross profit

5.1m

Gross profit Margin, %

51%

R&D expense

9.9m10.6m

General and administrative expense

10.2m28.8m

Operating expense total

20.1m39.5m

EBIT

(19.5m)(34.4m)

EBIT margin, %

(347%)

Interest expense

477.0k135.0k

Net Income

(20.5m)(34.8m)

Obalon Therapeutics Balance Sheet

Annual

USDFY, 2016FY, 2017

Cash

73.0m21.1m

Accounts Receivable

2.9m4.2m

Inventories

827.0k1.4m

Current Assets

78.1m51.8m

PP&E

717.0k1.3m

Total Assets

78.8m53.1m

Accounts Payable

595.0k1.3m

Current Liabilities

4.6m10.0m

Non-Current Liabilities

8.0m

Total Liabilities

14.5m18.0m

Additional Paid-in Capital

140.9m146.5m

Retained Earnings

(76.6m)(111.4m)

Total Equity

64.3m35.1m

Financial Leverage

1.2 x1.5 x

Obalon Therapeutics Cash Flow

Annual

USDFY, 2016FY, 2017

Net Income

(20.5m)(34.8m)

Depreciation and Amortization

192.0k330.0k

Accounts Receivable

(4.2m)

Inventories

(464.0k)(591.0k)

Accounts Payable

46.0k624.0k

Cash From Operating Activities

(19.4m)(30.6m)

Purchases of PP&E

(352.0k)(1.0m)

Cash From Investing Activities

6.2m(21.9m)

Cash From Financing Activities

82.8m613.0k

Interest Paid

527.0k562.0k

Income Taxes Paid

2.0k

Obalon Therapeutics Ratios

USDY, 2018

Financial Leverage

1.8 x
Report incorrect company information

Obalon Therapeutics Employee Rating

3.010 votes
Culture & Values
2.9
Work/Life Balance
2.5
Senior Management
3.0
Salary & Benefits
3.5
Career Opportunities
3.2
Source